GenSci's Profitability Remains Number One Among Chinese Biotech Companies

GeneScience Pharmaceuticals Co., Ltd. (GenSci), a leading
biopharmaceutical company in China focused on developing,
manufacturing and marketing protein therapeutic products, including
Somatropin, Filgrastim and Molgramostim, has been ranked number one in
profitability among Chinese biopharmaceutical companies for the second
quarter ended June 30, 2006, according to data compiled and released
by the Chinese official agency, the National Bureau of Statistics.

The first six months of 2006 saw a decline of drug prices in China
resulting from the government's tightened price control, stiff
competition and increased manufacturing costs. However, GenSci kept
its remarkable growth despite this adverse environment. Sales reached
RMB 89.88 (US 11.37) million for the period with a profit of RMB 39.23
(US 4.96) million. Although its revenue was ranked 40th among all of
the Chinese biopharmaceutical companies for the period, GenSci's
profit was ranked 14th. Overall, its profit margin was ranked No. 1 in
the country for the second consecutive year. GenSci's performance has
surpassed many Chinese state-owned pharmaceutical conglomerates whose
assets and sales are more than 10 times its size.

"We are very proud of what we have accomplished with one or two
major products," said Dr. Lei Jin, CEO of GenSci. "Traditionally,
GenSci's major revenue has been from our core product, Somatropin,
which maintains a dominant position in the domestic market. I am
especially glad to see a new driving source of revenue from liquid
Somatropin that we launched last year, and from the rapid sales growth
of Filgrastim." Looking forward to the next three years, Dr. Jin is
optimistic of GenSci's future, with a topical form of molgramostim
(currently in NDA) and two Phase II products, long-acting Somatropin
and Thymosin, awaiting market approvals from China's SFDA.

About GenSci

GenSci (www.gensci-china.com) is the leading biopharmaceutical
company in China that develops, manufactures and markets biological
therapeutics focused on endocrinology and related areas, aiming to
provide affordable and innovative biopharmaceutical products to
patients. The company is privately-held and headquartered in
Changchun, China. Products include: Jintropin somatropin (rhGH for
injection), Jintropin AQ somatropin liquid pen, Scimax filgrastim
(rhG-CSF injection), Granmac molgramostim (rhGM-CSF for injection),
Jintrotide (octreotide acetate for injection) and Jintrirelin
(triptorelin acetate injection). For more information, visit
www.gensci-china.com.